
Eptase1.5 millio
Beacon Pharmaceuticals PLC
Streptokinase is a thrombolytic (fibrinolytic) enzyme used exclusively in emergency, hospital-based settings under continuous medical supervision.
Streptokinase is a thrombolytic (fibrinolytic) enzyme used exclusively in emergency, hospital-based settings under continuous medical supervision. It is indicated for the following conditions:
Streptokinase therapy is typically followed by anticoagulation (e.g., heparin) to prevent re-thrombosis. It requires strict patient selection based on bleeding risk and time since symptom onset, and is administered only by trained personnel in a hospital or emergency care setting with facilities for continuous monitoring and management of bleeding complications.
Streptokinase is administered only by intravenous or intracoronary infusion by trained healthcare professionals in a hospital or emergency care setting, with continuous monitoring of vital signs, bleeding, and (where feasible) coagulation status.
| Indication | Dose |
|---|---|
| Acute myocardial infarction (IV) | 1,500,000 IU infused intravenously over 60 minutes |
| Acute myocardial infarction (intracoronary) | 20,000 IU bolus followed by 2,000 IU/minute for up to 60 minutes |
| Pulmonary embolism | Loading dose of 250,000 IU IV over 30 minutes, then 100,000 IU/hour for 24 hours |
| Deep vein thrombosis / arterial thromboembolism | Loading dose of 250,000 IU IV over 30 minutes, then 100,000 IU/hour for 24-72 hours, guided by clinical and laboratory response |
| Occluded arteriovenous cannula | 250,000 IU in 2 mL solution instilled slowly into each occluded limb of the cannula; clamp for 2 hours, then aspirate and flush |
Dosing must be individualized by the treating physician based on the indication, patient weight, bleeding risk, and clinical response. Concurrent or subsequent anticoagulant therapy is often required and should be guided by a specialist.
The most significant adverse effect of Streptokinase is bleeding, which can range from minor (bruising, oozing at puncture sites) to severe or life-threatening (gastrointestinal, genitourinary, retroperitoneal, or intracranial hemorrhage).
Patients are monitored closely during and after infusion for these effects; serious bleeding requires immediate discontinuation and appropriate emergency management.
Streptokinase is contraindicated in patients with:
Only true absolute contraindications are listed here; conditions that raise bleeding risk without being absolute (e.g., recent major surgery, recent trauma, pregnancy) are discussed under Precautions and Warnings and require careful individualized risk-benefit assessment.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.